• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Does Adding Methylergonovine to Oxytocin Reduce the Need for Additional Uterotonics Following Intrapartum Cesarean Delivery?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Masse et al. (Obstetrics and Gynecology, 2022) evaluated whether the administration of prophylactic methylergonovine in addition to oxytocin in patients undergoing intrapartum cesarean birth reduces the need for additional uterotonic agents

METHODS:

  • Single-center, placebo-controlled, randomized trial
  • Participants
    • Patients undergoing intrapartum cesarean birth
  • Interventions
    • Study group: Intervention: IV oxytocin (300 mL/minute) and IM methylergonovine 0.2 mg (1 mL)
    • Control: IV oxytocin (300 mL/minute) and IM saline (1 mL)
  • Study design
    • Sample size of 76 patients per group
    • Goal to detect a twofold decrease in the need for additional uterotonic agents based upon a 42% baseline
    • 80% power | Two-sided type 1 error of 5%
  • Primary outcome
    • Receipt of additional uterotonic agents
  • Secondary outcomes
    • Surgeon assessment of uterine tone
    • Incidence of postpartum hemorrhage (>1 L within the first 24 hours postpartum)
    • Quantitative blood loss
    • Blood transfusion

RESULTS:

  • Intervention: 80 patients | Control: 80 patients
  • Significantly fewer patients who were allocated to the methylergonovine group received additional uterotonic agents
    • Intervention: 20%
    • Control: 55%
    • Relative risk (RR) 0.4 (95% CI, 0.2 to 0.6)
  • Participants receiving methylergonovine were also more likely to have
    • Satisfactory uterine tone
      • Intervention: 80%
      • Control: 41%
      • RR 1.9 (95% CI, 1.5 to 2.6)
    • Lower incidence of postpartum hemorrhage
      • Intervention: 35%
      •  Control: 59%
      • RR 0.6 (95% CI, 0.4 to 0.9)
    • Lower mean quantitative blood loss
      • Intervention: 967 mL
      • Control: 1315 mL
      • Mean difference 348 (95% CI, 124 to 572)
    • Lower frequency of blood transfusion
      • Intervention: 5%
      • Control: 23%
      • RR 0.2 (95% CI, 0.1 to 0.6)

CONCLUSION:

  • In the setting of intrapartum cesarean delivery, adding prophylactic methylergonovine to oxytocin significantly reduced the need for additional uterotonic agents
  • The authors state

Prior studies have noted oxytocin resistance in laboring patients undergoing intrapartum cesarean birth

Continuous exposure of human myometrial cells to oxytocin leads to a loss in their capacity to respond to oxytocin

The administration of prophylactic methylergonovine in patients requiring intrapartum cesarean birth could therefore serve to improve uterine tone and decrease postpartum hemorrhage by facilitating uterine contraction through an alternative, non–oxytocin receptor–dependent pathway

Learn More – Primary Sources:

Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Patients Undergoing Intrapartum Cesarean Birth: A Randomized Controlled Trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Does the Addition of Uterotonics to Prophylactic Oxytocin Reduce PPH following Cesarean for Arrest of Labor
Cochrane Review 2018: Uterotonic Agents for PPH Prophylaxis
Meta-Analysis: Comparison of Medications for PPH Prevention During Cesarean Delivery
Postpartum Hemorrhage – Medications to Treat Uterine Atony 

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site